Home

Adrian Senderowicz

CIK 1616230 · Chief Medical Officer · last filed 2026-06-15

Adrian Senderowicz is a Chief Medical Officer who has filed 37 SEC Form 4 insider transactions across 4 companies since 2014. The most recent filing, for PBYI, was dated Jun 15, 2026. Across all open-market trades the lifetime net is −$2.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $257.9K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$257.9K

Companies

4

Total Filings

37

Lifetime Open-Market Net

-$2.33M

Filer Profile

Reported Address
C/O PUMA BIOTECHNOLOGY, INC.
10880 WILSHIRE BOULEVARD, SUITE 1700
LOS ANGELES, CA
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PBYI Director 27,000 $9.55 $257.9K -$1.10M 20 2026-06-15
CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted Chief Medical Officer 15,884 $33.99 $539.9K -$1.24M 6 2020-05-13
Dare Bioscience, Inc. (CERU) Delisted SVP, Chief Medical Officer — — — $0 5 2017-01-09
Ignyta, Inc. (RXDX) Delisted Chief Medical Officer — $199.92 — $0 2 2015-01-09

Recent Filings

37 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-15 PBYI Mixed — -$194.3K EDGAR
2026-06-12 PBYI Notice (144) −27,000 -$196.0K EDGAR
2025-06-17 PBYI Sell (S) −27,000 -$91.8K EDGAR
2025-06-13 PBYI Notice (144) −27,000 -$91.8K EDGAR
2025-06-13 PBYI Grant (A) +27,000 $0 EDGAR
2024-06-21 PBYI Grant (A) +27,000 $0 EDGAR
2024-06-17 PBYI Sell (S) −27,000 -$89.8K EDGAR
2024-06-13 PBYI Notice (144) −27,000 -$97.1K EDGAR
2023-06-15 PBYI Mixed — -$93.3K EDGAR
2023-06-13 PBYI Notice (144) −27,000 -$93.4K EDGAR
Showing 1–10 of 37
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.